Cedric Coulouarn

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5120878/publications.pdf

Version: 2024-02-01

57 papers	2,652 citations	331670 21 h-index	214800 47 g-index
59 all docs	59 docs citations	59 times ranked	4068 citing authors

#	Article	IF	Citations
1	The proteaseâ€inhibitor SerpinB3 as a critical modulator of the stemâ€like subset in human cholangiocarcinoma. Liver International, 2022, 42, 233-248.	3.9	15
2	One stone, two birds: circACTN4, a nexus for a coordinated activation of Hippo and Wnt/Î²-catenin pathways in cholangiocarcinoma. Journal of Hepatology, 2022, 76, 8-10.	3.7	5
3	Emerging roles of circular RNAs in liver cancer. JHEP Reports, 2022, 4, 100413.	4.9	10
4	TGFÎ²â€induced FOXS1 controls epithelialâ€“mesenchymal transition and predicts a poor prognosis in liver cancer. Hepatology Communications, 2022, 6, 1157-1171.	4.3	9
5	Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut, 2022, , gutjnl-2022-327099.	12.1	11
6	Long Noncoding RNAs in Cholangiocarcinoma. Hepatology, 2021, 73, 1213-1226.	7.3	11
7	Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opinion on Therapeutic Targets, 2021, 25, 153-162.	3.4	11
8	The Consumption of Cholesterol-Enriched Diets Conditions the Development of a Subtype of HCC with High Aggressiveness and Poor Prognosis. Cancers, 2021, 13, 1721.	3.7	13
9	Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer. Journal of Hepatology, 2021, 74, 1018-1020.	3.7	2
10	The noncoding MIR100HG RNA enhances the autocrine function of transforming growth factor Î² signaling. Oncogene, 2021, 40, 3748-3765.	5.9	18
11	DNA Methylation of TGFÎ² Target Genes: Epigenetic Control of TGFÎ² Functional Duality in Liver Cancer. Cells, 2021, 10, 2207.	4.1	7
12	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. Journal of Experimental Medicine, 2021, 218, .	8.5	20
13	A Minimal Subset of Seven Genes Associated with Tumor Hepatocyte Differentiation Predicts a Poor Prognosis in Human Hepatocellular Carcinoma. Cancers, 2021, 13, 5624.	3.7	5
14	Molecular classification of cholangiocarcinoma. Current Opinion in Gastroenterology, 2020, 36, 57-62.	2.3	26
15	Moderate chronic ethanol consumption exerts beneficial effects on nonalcoholic fatty liver in mice fed a high-fat diet: possible role of higher formation of triglycerides enriched in monounsaturated fatty acids. European Journal of Nutrition, 2020, 59, 1619-1632.	3.9	10
16	A novel immunosuppression-based classification of liver tumors opens new perspectives for adapted therapeutic strategies. EBioMedicine, 2020, 54, 102737.	6.1	0
17	Molecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma. British Journal of Cancer, 2020, 123, 72-80.	6.4	21
18	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	17.8	1,155

#	Article	IF	Citations
19	Ganglioside patterns in the human cholangiocarcinoma stem cell subset A. Digestive and Liver Disease, 2020, 52, e11.	0.9	0
20	Transforming Growth Factorâ€Î² and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma. Hepatology, 2019, 69, 222-236.	7.3	85
21	SAT-399-The profile on intracellular gangliosides correlates with the malignant phenotype of cholangiocarcinoma cells and modulates cells adhesion. Journal of Hepatology, 2019, 70, e810.	3.7	0
22	THU-452-TFOX, a novel TGF-beta target gene, switches TGF-beta activity toward EMT during tumor progression of human hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e357-e358.	3.7	0
23	Transforming Growth Factor-Beta (TGFÎ²) Signaling Pathway in Cholangiocarcinoma. Cells, 2019, 8, 960.	4.1	25
24	Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma. Digestive and Liver Disease, 2019, 51, 1337-1343.	0.9	45
25	Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver International, 2019, 39, 43-62.	3.9	54
26	GDF11 exhibits tumor suppressive properties in hepatocellular carcinoma cells by restricting clonal expansion and invasion. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1540-1554.	3.8	22
27	Ganglioside composition correlates with the malignant phenotype of cholangiocarcinoma cells and modulates cell adhesion. Digestive and Liver Disease, 2019, 51, e7.	0.9	0
28	The bidirectional crosstalk between metastatic uveal melanoma cells and hepatic stellate cells engenders an inflammatory microenvironment. Experimental Eye Research, 2019, 181, 213-222.	2.6	20
29	Exosomal circRNAs: new players in the field of cholangiocarcinoma. Clinical Science, 2019, 133, 2239-2244.	4.3	35
30	A novel transforming growth factor betaâ€induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma. Hepatology Communications, 2018, 2, 254-269.	4.3	37
31	The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma. Clinical Cancer Research, 2018, 24, 4282-4296.	7.0	68
32	AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of Î²-catenin activation. Journal of Hepatology, 2018, 68, 1203-1213.	3.7	78
33	SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance. British Journal of Cancer, 2018, 119, 1358-1366.	6.4	31
34	Transforming growth factor-Î²eta and AXL collaborate to induce CXCL5 and neutrophil infiltration in hepatocellular carcinoma. Journal of Hepatology, 2018, 68, S674-S675.	3.7	2
35	Co-exposure to benzo[a]pyrene and ethanol induces a pathological progression of liver steatosis in vitro and in vivo. Scientific Reports, 2018, 8, 5963.	3.3	36
36	The release of proâ€inflammatory cytokines is mediated via mitogenâ€activated protein kinases rather than by the inflammasome signalling pathway in keratinocytes. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 827-838.	1.9	9

#	Article	IF	Citations
37	Benzo[a]pyrene and ethanol exert a high toxicity potential in steatotic HepaRG cells: possible role of low NDUFA4L2 expression. Journal of Hepatology, 2017, 66, S402.	3.7	0
38	Local Anesthetics Inhibit the Growth of Human Hepatocellular Carcinoma Cells. Anesthesia and Analgesia, 2017, 125, 1600-1609.	2.2	47
39	Identification of invasion-addicted genes driven by transforming growth factor-beta in hepatocellular carcinoma. Journal of Hepatology, 2017, 66, S637-S638.	3.7	0
40	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. Journal of Hepatology, 2017, 66, 102-115.	3.7	130
41	Landscape of genomic alterations in hepatocellular carcinoma: current knowledge and perspectives for targeted therapies. Hepatobiliary Surgery and Nutrition, 2017, 6, 404-407.	1.5	8
42	TGF-Î²1 and TGF-Î²2 abundance in liver diseases of mice and men. Oncotarget, 2016, 7, 19499-19518.	1.8	52
43	Gene expression profiling of the tumor microenvironment in human intrahepatic cholangiocarcinoma. Genomics Data, 2016, 7, 229-232.	1.3	21
44	Integrative Genomic Analysis Identifies the Core Transcriptional Hallmarks of Human Hepatocellular Carcinoma. Cancer Research, 2016, 76, 6374-6381.	0.9	48
45	Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma. Journal of Surgical Research, 2016, 203, 441-450.	1.6	19
46	De novo HAPLN1 expression hallmarks Wnt-induced stem cell and fibrogenic networks leading to aggressive human hepatocellular carcinomas. Oncotarget, 2016, 7, 39026-39043.	1.8	29
47	LKB1 and Notch Pathways Interact and Control Biliary Morphogenesis. PLoS ONE, 2015, 10, e0145400.	2.5	17
48	Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability. Journal of Vascular and Interventional Radiology, 2015, 26, 1874-1878.e2.	0.5	5
49	Modulating the activation of hepatic stellate cells: A cunning way for metastatic cells to create a permissive soil for seeding in the liver?. Hepatology, 2015, 61, 37-40.	7.3	5
50	P0234 : A TGF-beta genomic signature in intrahepatic cholangiocarcinoma highlights a novel long non coding RNA located in the nuclear paraspeckles of tumor cholangiocytes. Journal of Hepatology, 2015, 62, S394-S395.	3.7	0
51	Regulation of hepatic cardiolipin metabolism by TNFÎ±: Implication in cancer cachexia. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 1490-1500.	2.4	28
52	Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma. Journal of Surgical Research, 2014, 192, 117-123.	1.6	37
53	P82 TGF-Î² SIGNALING REGULATOR EXPRESSION IN HUMAN HCC: RESULTS FROM MICROARRAY DATA META ANALYSES. Journal of Hepatology, 2014, 60, S93-S94.	3.7	0
54	Inflammatory cytokines promote the retrodifferentiation of tumorâ€derived hepatocyteâ€like cells to progenitor cells. Hepatology, 2014, 60, 2077-2090.	7.3	75

#	Article	IF	Citations
55	O59 MICE WITH AXIN-1 LIVER SPECIFIC DELETION DEVELOP HEPATOCELLULAR CARCINOMAS WITHOUT BETA-CATENIN ACTIVATION. Journal of Hepatology, 2014, 60, S24-S25.	3.7	0
56	Stellate cells and the development of liver cancer: Therapeutic potential of targeting the stroma. Journal of Hepatology, 2014, 60, 1306-1309.	3.7	122
57	Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology, 2013, 58, 1992-2000.	7.3	113